Does anyone else think we are going to looking at crazy amounts of $$, when we look at targeting just 1% of sufferers to make a 10x increase in shareprice.
BOT have the only next generation medication for the condition, therefore not best in class, Sofdra is the ONLY medication in its class!!
I believe management will be secretly planning for when BOT have >20% of people with this condition wanting BOT's product, why would people not want the best medication (really the only prescription medication), i know i would.
BOT can only really skyrocket from here, it will be a happy couple of years for long termers.
BOT - Anything but charting, page-9275
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
-0.010(2.41%) |
Mkt cap ! $725.6M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 42.5¢ | 39.5¢ | $3.680M | 8.989M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 297011 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 12027 | 3 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |